Your Spare Parts Now Get Graded: CMS Decides Organs Should Actually Reach People

Healthcare professionals coordinate organ transport and review a checklist in a bright clinical operations room

By Dakota Jones
Desk: Political & Government, Public Policy & Regulatory.

Intro

A donated organ is not a performance metric. It is a chance for someone to live longer. So when the federal government updates the rules for organizations that recover organs and coordinate their delivery, one basic question should come first: Did the organ actually reach a patient?

On October 30, 2026, the U.S. Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, finalized a rule tightening oversight of Organ Procurement Organizations, or OPOs. These nonprofits connect donor hospitals with transplant programs and coordinate the recovery and delivery of organs.

The stakes are plain. CMS says more than 49,000 transplants took place in the United States in 2025, while over 100,000 Americans are waiting. The rule is meant to strengthen accountability and help more donated organs reach transplant patients. It is a consequential policy update, and, as we’ll get to, it does not take effect the moment the press release drops.

What happened

The final rule builds on the first Trump administration’s 2020 OPO rule, which established performance measures and competition for open donation service areas. CMS reports that since the 2020 rule, organ donations have increased 36% nationwide and transplants have increased 30%. Those are agency-reported changes, not a guarantee that any particular patient will get an organ sooner.

The new rule sharpens how CMS oversees OPOs and measures their work. Here are the key changes:

  1. Research is not the same thing as transplantation. A donor whose pancreas is recovered only for islet cell research will still count toward an OPO’s donation rate. But that pancreas will no longer count toward its transplantation rate unless an actual transplant occurs. In other words, research activity can be recognized as donation, but it cannot be dressed up as a transplant. CMS also requires OPOs to document what happens to organs sent for research.

  2. Patient safeguards get clearer rules. The rule defines “unsound medical practices,” clarifying when CMS can immediately decertify a noncompliant OPO under its existing authority. OPOs must also have policies to identify, investigate and prevent adverse events. That’s the kind of paperwork nobody hopes will be needed, and the kind you want in place before it is.

  3. Leadership and handoffs face requirements. An OPO medical director must hold a license in at least one state or territory the organization serves. When an OPO changes, the outgoing organization must cooperate with its successor. The incoming organization must submit a transition plan and progress updates to help maintain operations.

  4. Decertification and appeals are more clearly spelled out. CMS clarifies pathways for decertification and codifies an appeals process, including discretionary review by the CMS Administrator. The rule also removes a certification requirement tied to OPOs recertified between 2002 and 2005.

A sealed medical transport cooler beside a checklist and tablet in a clean clinical setting

Competition remains part of the system. High-performing OPOs may compete for multiple donation service areas, or DSAs. The geographic areas an OPO serves. CMS also retains its existing three-tier performance framework. Tier 2 service areas must face competition, but Tier 2 status alone is not grounds for decertification. OPOs whose service areas are all Tier 3, the lowest-performing tier, will be decertified and cannot compete for another open area.

One timing detail deserves a highlighter. The rule is final, but not instantly active. JBizNews reports that Federal Register publication is scheduled for November 3, and the rule takes effect 60 days after publication. That publication date is Election Day. Washington has managed to schedule a technical regulatory milestone for the same day Americans are voting. Organ procurement, however, is one of the few issues where people across parties may have a relative, friend or neighbor waiting on the outcome.

A clinical quality team reviews anonymized process charts and an audit checklist

Why it matters

The transplant system needs more than good intentions. It needs reliable coordination, patient safeguards and performance measures that describe what happened, not what might have happened in a research setting.

The pancreas provision is a small technical change with a straightforward logic. If a pancreas is used only for islet cell research and no transplant takes place, that activity should not raise an OPO’s transplantation rate. The donation still counts as donation. The transplant rate, meanwhile, should reflect transplants. It is not a radical accounting theory. It is what the words mean.

The rule’s transition requirements matter, too. Changing which organization serves an area could disrupt a process that depends on coordination among donor hospitals, OPOs and transplant programs. Requiring cooperation from the outgoing OPO and a plan with progress updates from the incoming one is meant to help keep operations moving through that handoff.

And the tier framework is more nuanced than “underperform, get shut down.” Tier 2 means competition, not automatic decertification. The all-Tier-3 consequence is different: those OPOs will be decertified and cannot compete for another open service area. Keeping those distinctions straight matters. So does keeping the calendar straight: finalized policy is not the same as policy already in effect.

The rule also complements HHS’s Kidney Care National Plan and builds on the 2019 Executive Order Advancing American Kidney Health. CMS says the prior reforms coincided with nationwide increases in donations and transplants; the new provisions add oversight and clarify the scorecard.

Quick answers

Does the rule take effect on Election Day? No. It is scheduled to be published in the Federal Register on November 3, 2026, and takes effect 60 days after publication.

Does Tier 2 status alone get an OPO decertified? No. Tier 2 service areas must face competition, but Tier 2 status by itself is not grounds for decertification.

Will this rule guarantee an organ for a specific patient? No. It changes oversight and performance requirements; it does not promise that an individual patient will receive an organ sooner.

Verdict

The basic idea is almost offensively sensible: if an organ is counted as a transplant, it should have been transplanted into a patient. Research matters. Donations matter. Accurate measures matter, too. One should not quietly substitute for another.

There are real policy details to watch, including how CMS applies the decertification rules and manages service-area transitions. And the effective date matters: this is finalized, but not instantly operational. Still, demanding that donated organs be tracked, that unsafe practices have consequences and that transplant rates reflect actual transplants is a solid place to start.

The sarcasm writes itself. The substance is genuinely good. For more coverage of policy and government, visit LD3 Productions’ Political & Government desk.

Sources